Precision Targeted Therapy with BLU-667 for RET-Driven Cancers-Reference-Cited by-同舟云学术

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers

Published:2018-04-15 Issue:7 Volume:8 Page:836-849
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Subbiah Vivek,Gainor Justin F.,Rahal Rami^ORCID,Brubaker Jason D.,Kim Joseph L.^ORCID,Maynard Michelle,Hu Wei,Cao Qiongfang,Sheets Michael P.,Wilson Douglas,Wilson Kevin J.,DiPietro Lucian,Fleming Paul,Palmer Michael,Hu Mimi I.,Wirth Lori,Brose Marcia S.,Ou Sai-Hong Ignatius,Taylor Matthew,Garralda Elena,Miller Stephen,Wolf Beni,Lengauer Christoph,Guzi Timothy,Evans Erica K.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 320 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications;European Journal of Medicinal Chemistry;2024-10

2. Efficacy and safety of pralsetinib in patients with RET fusion positive non–small cell lung cancer: An observational real world study;Lung Cancer;2024-10

3. Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification;JCO Precision Oncology;2024-09

4. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

5. REThinking the role of the RET oncogene in breast cancer;Frontiers in Oncology;2024-08-01